195 related articles for article (PubMed ID: 37864709)
1. Mitochondria-related lncRNAs: predicting prognosis, tumor microenvironment and treatment response in lung adenocarcinoma.
Zhou Q; Xiong J; Gao Y; Yi R; Xu Y; Chen Q; Wang L; Chen Y
Funct Integr Genomics; 2023 Oct; 23(4):323. PubMed ID: 37864709
[TBL] [Abstract][Full Text] [Related]
2. The necroptosis-related signature and tumor microenvironment immune characteristics associated with clinical prognosis and drug sensitivity analysis in stomach adenocarcinoma.
Yang B; Wang Y; Liu T; Zhang M; Luo T
Aging (Albany NY); 2024 Mar; 16(7):6098-6117. PubMed ID: 38546403
[TBL] [Abstract][Full Text] [Related]
3. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib metabolism-related lncRNAs for the prediction of prognosis, tumor microenvironment and drug sensitivity in lung adenocarcinoma.
Guo Z; Zhang X; Yang D; Hu Z; Wu J; Zhou W; Wu S; Zhang W
Sci Rep; 2024 May; 14(1):10348. PubMed ID: 38710798
[TBL] [Abstract][Full Text] [Related]
6. Immunoprognostic model of lung adenocarcinoma and screening of sensitive drugs.
Liang P; Li J; Chen J; Lu J; Hao Z; Shi J; Chang Q; Zeng Z
Sci Rep; 2022 May; 12(1):7162. PubMed ID: 35504892
[TBL] [Abstract][Full Text] [Related]
7. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
Li F; Niu Y; Zhao W; Yan C; Qi Y
Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
[TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
Zeng C; Yu H; Liu X; Liu Q; Jin J
Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
[TBL] [Abstract][Full Text] [Related]
9. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.
Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L
Aging (Albany NY); 2024 Jun; 16():. PubMed ID: 38862217
[TBL] [Abstract][Full Text] [Related]
10. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of tryptophan metabolism-related lncRNAs in lung adenocarcinoma prognosis and immune response.
Gao M; Wang M; Chen Y; Wu J; Zhou S; He W; Shu Y; Wang X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):171. PubMed ID: 38558328
[TBL] [Abstract][Full Text] [Related]
12. An exosomes-related lncRNA prognostic model correlates with the immune microenvironment and therapy response in lung adenocarcinoma.
Chu D; Chen L; Li W; Zhang H
Clin Exp Med; 2024 May; 24(1):104. PubMed ID: 38761234
[TBL] [Abstract][Full Text] [Related]
13. Identification of a RNA-Seq Based Prognostic Signature with Seven Immune-Related lncRNAs for Lung Adenocarcinoma.
You J; Fang W; Zhao Q; Chen L; Chen L; Chen F
Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739047
[TBL] [Abstract][Full Text] [Related]
14. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma.
Sun D; Zhang C
Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766
[TBL] [Abstract][Full Text] [Related]
15. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
16. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
[TBL] [Abstract][Full Text] [Related]
17. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
18. Prognostic value and immune landscapes of anoikis-associated lncRNAs in lung adenocarcinoma.
Wu B; Zhang X; Feng N; Guo Z; Gao L; Wan Z; Zhang W
Aging (Albany NY); 2024 Feb; 16(3):2273-2298. PubMed ID: 38319706
[TBL] [Abstract][Full Text] [Related]
19. Developing a RiskScore Model based on Angiogenesis-related lncRNAs for Colon Adenocarcinoma Prognostic Prediction.
Li X; Lei J; Shi Y; Peng Z; Gong M; Shu X
Curr Med Chem; 2024; 31(17):2449-2466. PubMed ID: 37961859
[TBL] [Abstract][Full Text] [Related]
20. Integrated analysis of hypoxia-associated lncRNA signature to predict prognosis and immune microenvironment of lung adenocarcinoma patients.
Shao J; Zhang B; Kuai L; Li Q
Bioengineered; 2021 Dec; 12(1):6186-6200. PubMed ID: 34486476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
